bioAffinity Technologies Reports Second Quarter 2023 Financial Results and Provides Business Update
Retrieved on:
Monday, August 14, 2023
Oncology, Health, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Exercise, Department of Defense Serum Repository, Medicaid, University, Observational study, CPT, CD320, Marketing, Gastric lavage, Lung cancer, Research, BIAF, RNA, Lung, Military personnel, Small RNA, American Medical Association, Medicare, DOD, Congress, COVID-19, Patient, Physician, Flow cytometry, AMA, CFO, City, LRP2, Therapy, International Society, Pharmaceutical industry
Revenue for the second quarter of 2023 was $20,000, compared with $1,000 for the prior-year period.
Key Points:
- Revenue for the second quarter of 2023 was $20,000, compared with $1,000 for the prior-year period.
- Research and development expenses were $335,000 for the second quarter of 2023, compared with $248,000 for the comparable period in 2022.
- Clinical development expenses were $35,000 for the second quarter of 2023, compared with $28,000 for the second quarter of 2022.
- Selling, general and administrative expenses were $1.4 million for the second quarter of 2023, compared with $409,000 for the comparable period in 2022.